Enhancing Effectiveness of Immune Checkpoint Therapy in Neuroblastoma |
Children’s Hospital Los Angeles / Shahab Asgharzadeh, MD |
Innovation Grants |
2015 |
California |
Antibody Targeted Natural Killer Cell-Derived Extracellular Vesicles for the Treatment of Childhood Acute Lymphoblastic Leukemia and Neuroblastoma |
Children’s Hospital Los Angeles / Robert Seeger, MD & Alan Wayne, MD |
Innovation Grants |
2015 |
California |
Circulating Repetitive Element RNAs as an Osteosarcoma Marker |
Children’s Hospital Los Angeles / David Cobrinik, MD/PhD |
Innovation Grants |
2018 |
California |
The role of OCT4 in self-renewal signaling and drug-resistance of childhood acute lymphoblastic leukemia
|
Children’s Hospital Los Angeles / Markus Muschen |
Innovation Grants |
2008 |
California |
Preclinical Studies of Gli1 Inhibition in Ewing Family Tumors
|
Children’s Hospital Los Angeles / William May |
Innovation Grants |
2008 |
California |
Physical Properties of Drug-Resistant Leukemia Cells |
Children’s Hospital Los Angeles / Yong-mi Kim, MD/PhD |
Innovation Grants |
2018 |
California |
Predicting Outcome for Patients with Metastatic Neuroblastoma by Analysis of Bone Marrow and Blood for a Neuroblastoma Gene Expression Signature |
Children’s Hospital Los Angeles / Robert Seeger |
Innovation Grants |
2010 |
California |
Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy |
Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD |
Innovation Grants |
2019 |
Ohio |
Novel STAT3 drug development for childhood osteosarcoma therapy using drug repositioning |
Research Institute at Nationwide Children's Hospital / Jiayuh Lin, PhD |
Innovation Grants |
2012 |
Ohio |
Improving Immune-Mediated Oncolytic Viral Therapy: Engineering Tumor Vaccine Elements into the Virus |
Research Institute at Nationwide Children's Hospital / Kevin Cassady, MD & Christopher Walker, PhD |
Innovation Grants |
2016 |
Ohio |